Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - May 2014


Europe Drug Discovery Summit

06 May 2014 - 09 May 2014 - Berlin, Germany



Bookmark and Share


We are pleased to announce the Europe Drug Discovery Summit, which will be held May 6-9, 2014 in Berlin, Germany. The summit is a forum for colleagues from industry and academia, as well as across multiple disciplines, to gather and share complementary perspectives on the latest research and breakthrough. The summit includes four individual conferences that will take place over the course of the four days: Cancer Drug Research & Development (May 6-7, 2014) This conference will cover topics such as cancer targets, kinase inhibitors, drug resistance, combination therapy, cancer metabolism, invasion and metastasis, epigenetic regulators and immunotherapy. Tissue Models & Drug Screening (May 6-7, 2014) Physically relevant model systems have changed the way we look at early-stage drug discovery research. Come to learn about advances in HCA and phenotypic screening, using 3D models for target validation, and much more. Drug Design & Medicinal Chemistry (May 8-9, 2014) This meeting will discuss emerging target classes, advances in antibody drug conjugates and other methods for targeted drug delivery, new approaches in flow chemistry, and much more. Protein Kinases in Drug Discovery (May 8-9, 2014) Leading experts will focus on drug discovery and design, novel drug targets, kinase inhibitor development, including cancer treatments, and lessons from pre-clinical models and clinical development for use in creating personalized therapies. We hope you’ll be able to join us for exciting scientific presentations and dedicated networking sessions.

Further information
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Immune System 'On Switch' Breakthrough Could Lead to Targeted Drugs
A crucial 'on switch' that boosts the body's defenses against infections has been successfully identified in new scientific research.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!